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Abstract
Background: Because of its propensity to sequester in the placental intervillous space, Plasmodium falciparum can evade
detection by peripheral smear in women with placental malaria (PM). We evaluated host biomarkers as potential indicators
of occult PM infections.
Methods and Findings: Using a case-control design, we evaluated the ability of biomarkers to identify PM in the absence of
circulating peripheral parasites (n=24) compared to placental smear-negative controls (n=326). We measured levels of
biomarkers (C3a, C5a, CRP, angiopoietin-1, angiopoietin-2, sTie-2, sEndoglin, VEGF, sFlt-1, tissue factor, and leptin) in
maternal peripheral plasma at delivery. Using ROC curve analysis, we assessed the ability of clinical parameters and
biomarkers to accurately detect PM infections identified by placental smear. We show that decreases in sFlt-1 and leptin and
increases in CRP were associated with occult PM infections (p,0.01) and correlated with placental parasitaemia (p,0.01).
Individually, all markers had moderate ability to diagnose occult PM infections with areas under the ROC between 0.62 and
0.72. In order to improve diagnostic performance, we generated simple scoring systems to identify PM infections using
either a clinical score (0–2), a biomarker score (0–3) or a clinical plus biomarker score (0–5). The combinatorial model that
incorporated both clinical parameters and biomarkers had an area under curve (AUC) of 0.85 (95% CI, 0.81-0.89), which was
significantly better at identifying occult PM infections than the clinical score alone (p=0.001).
Conclusion: These data suggest that host biomarkers in the maternal peripheral blood may improve the detection of PM in
the absence of peripheral parasitaemia.
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Introduction
Every year 85 million pregnant women are at risk of infection by the
malaria parasite Plasmodium falciparum [1]. Malaria in pregnancy (MIP)
may lead to adverse consequences for both the mother and the fetus,
including severe maternal anemia, spontaneous abortion, stillbirth and
low birth weight (LBW). In areas of unstable transmission of P.
falciparum, mothers are at increased risk of severe malarial disease,
including cerebral malaria and hypoglycaemia [2]. As the level of
endemicity and prior clinical immunity to malaria increases, MIP is
more likely to be asymptomatic or paucisymptomatic [2].
The proclivity of P. falciparum-infected erythrocytes (IE) to bind
to chondroitin-sulfate A (CSA) in the placental intervillous space
[3] can make it difficult to detect placental malaria (PM) by either
microscopic examination of Giemsa-stained peripheral blood
smears or point-of-care rapid diagnostic testing (RDT) alone
[4,5,6]. Occult placental malaria may still lead to adverse
pregnancy outcomes. One strategy to decrease pregnancy-related
malaria complications is intermittent preventive treatment in
pregnancy (IPTp), the widespread administration of antimalarials
(typically sulfadoxine-pyrimethamine) to pregnant women irre-
spective of their infection status at two or more scheduled
antenatal visits during pregnancy [7]. Although IPTp has reduced
infant low birth weight by 43% [2], declining malaria transmission
and increasing resistance to sulfadoxine-pyrimethamine will
change the cost-benefit ratio for IPTp, potentially favoring
intermittent screening and treatment (IST) involving newer, more
costly and potentially less safe therapeutic agents [8]. Given the
limitations of traditional and field diagnostics to detect placental
malaria, the identification of biomarkers present in the maternal
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peripheral parasitemia, could minimize unnecessary drug treat-
ment during pregnancy, improve the sensitivity of IST to detect
placental malaria, reduce drug pressure and the selection of
resistant parasites, and improve maternal and fetal outcomes.
Because occult PM induces a local host response in the placenta,
and soluble components of the placental compartment may
circulate in the peripheral blood, we evaluated a number of host
proteins as potential candidate biomarkers for the detection of
placental malaria, in the absence of detectable circulating
parasites. We measured markers of inflammation (C-reactive
protein), complement activation (C3a, C5a), angiogenesis (angio-
poietin-1, angiopoietin-2, soluble Tie-2, vascular endothelial
growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFlt-1),
and soluble Endoglin), coagulation (tissue factor), and nutrient
availability (leptin). Our results indicate that decreases in sFlt-1
and leptin and an increase in CRP in peripheral plasma were
associated with the presence of placental parasites.
Methods
Ethics Statement
Ethical approval for this study was granted from The College of
Medicine Research Ethics Committee in Blantyre, Malawi
(COMREC) and all women gave written informed consent for
enrolment into the study.
Study Population
From 2001-2006, a cross-sectional study was carried out in
Blantyre, Malawi, in which pregnant women were prospectively
recruited at the Gogo Chatinkha Banda Maternity Unit of Queen
Elizabeth Central Hospital. Upon delivery, a thick blood film was
prepared from the cut surface of the placenta, and women were
recruited as cases if they were positive for placental malaria,
delivered a live singleton newborn, and had a peripheral blood
thick film that was negative for malaria parasites. Twenty-one
women were excluded from the study because they had malaria
parasites detected by peripheral smear, but not placental smear.
Age and gravidity-matched controls (peripheral and placental
smear negative for malaria) were chosen in a 2:1 ratio. Controls
enrolled based on a negative placental smear were not reclassified
as cases based on the identification of parasites by subsequent
histology, as these sub-microscopic infections were not associated
with significantly different clinical outcomes than histology
negative controls in this cohort. Placental and peripheral EDTA
plasma samples were collected after women had given their
informed consent, and samples were stored at -80uC until testing.
Biomarker ELISAs
Plasma concentrations of biomarkers C5a, angiopoietin (Ang)-1,
A n g - 2 ,s T i e - 2 ,s E n d o g l i n ,V E G F ,s F l t - 1 ,l e p t i n ,a n dC R P( D u o S e t s ,
R&D Systems, Minneapolis, MN) were measured in peripheral plasma
by ELISA, as described [9]. C3a (capture: clone 354113, detection:
purified PAb, Goat IgG) and tissue factor (capture: clone 323514,
detection: PAb, goat IgG) were measured using antibody pairs (R&D
Systems, Minneapolis, MN) with biotin swine anti-goat IgG (human
and mouse adsorbed, clone CLCC50015) as a secondary antibody as
described previously [9]. ELISAs were performed in 2009 by a single
experienced technician who was blinded to the microscopy results
during sample testing.
Statistical Analysis
GraphPad Prism v5, SPSS v16, and MedCalc software were
used for analysis. Comparisons of continuous variables were
performed using the Mann-Whitney U test and Spearman rank
correlation coefficient. Comparisons of proportions were per-
formed using Pearson Chi-square test or Fisher’s exact test, as
appropriate. Odds ratios (OR) were calculated using Pearson’s
Chi-square. The diagnostic accuracy of biomarkers and laboratory
findings were assessed using non-parametric receiver operating
characteristic (ROC) curves, and the areas under the ROC (AUC)
were compared using the method of Delong et al. [10]. Biomarker
cut-points were determined using the Youden index (J =
max[sensitivity + specificity – 1]).
Results
Description of Study Population
A total of 465 women with live singleton deliveries were
included in the study. Of these women, 326 were peripheral and
placental smear-negative for malaria and 139 were PM-positive
based on placental smears. Of the 139 placental smear-positive
women, 24 had negative peripheral smears. Over half (53.4%) of
the placental smear-negative women had histologic evidence of
active malaria infection (parasites 6 pigmented fibrin/mononu-
clear cells) and 16% of women had histologic findings indicating
past infection [11]. However, there were no differences in
peripheral blood biomarkers, maternal hemoglobin, or fetal
outcome (gestational age or birth weight) in placental smear-
negative women with histologically defined PM infections
compared to those with no detectable placental parasites
(Supplemental information, Table S1). Tissue factor was reduced
in histology-positive PM compared to histology-negative controls;
however, this result was not consistent in women with smear
positive infections and the biomarker had poor discriminatory
ability. Histology-only infections were not associated with clinical
signs of disease or clinically relevant outcomes (e.g. low birth
weight) in this population. Therefore, women were classified
according to the study design and cases represent smear positive
infections. In order to evaluate biomarkers in maternal peripheral
plasma that were the most sensitive for placental-specific
infections, the 326 peripheral and placental smear-negative
women were compared to women who were PM positive without
detectable infections by peripheral smear. The study population is
described in Table 1.
Women with placental smear-positive PM had a significantly
lower median peripheral-blood hemoglobin concentration ([Hb])
than placental smear-negative women (10.9 g/dL vs. 12.3 g/dL,
p=0.003, Mann-Whitney U test) (Table 1). Anemia (peripheral
blood [Hb] ,11 g/dL) in the mother was associated with a 3.3-
fold (95% CI, 1.4–7.6) increased odds of PM. Women with PM
more commonly reported non-specific symptoms (fever, chills,
headache) within one week prior to delivery (p,0.0001) (Table 1).
The presence of one or more of the above symptoms was
associated with a 7.0-fold (2.9–16.6) increased odds of placental
infection (p,0.0001).
sFlt-1, Leptin and CRP are Clinically Informative
Biomarkers of Placental Malaria Infection
We included a number of biomarkers in our analysis that have
previously been shown to be altered in the peripheral blood in
women with placental malaria, including CRP [6,12], comple-
ment C5a [13], the angiopoietin (Ang) family of Ang-1, Ang-2 and
a soluble form of their cognate receptor, Tie-2 (sTie-2) [14], anti-
angiogenic proteins sFlt-1 and sEndoglin [15], and leptin [16].
Median Ang-1, sFlt-1, and leptin levels were significantly lower,
and median CRP levels were significantly higher in women with
placental malaria than in uninfected controls (Figure 1, Table 2).
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placental parasite density on placental blood smear (Spearman’s
rho, p-value): Ang-1, -0.110, p=0.044; sFlt-1, -0.174, p=0.001;
leptin, -0.203, p,0.001; and CRP, 0.188, p,0.001. Ang-2 was the
only marker significantly associated with placental mononuclear
cell counts, as assessed by histology (0.141, p=0.009).
We assessed the diagnostic accuracy of our biomarkers using
receiver operating characteristic (ROC) curve analysis (Figure 1).
sFlt-1, leptin and CRP all had AUC $ 0.70 for discrimination
between cases and controls, and provided significant discrimina-
tion in univariable analysis after applying a correction factor for
multiple comparisons (Table 2, Figure1). We used the Youden
index to create a cut-point for each biomarker, and low sFlt-1
(,16.9 ng/mL), low leptin (,8.8 ng/mL) and high CRP
(.30.5 mg/mL) were associated with increased odds ratios (95%
CI) of placental malaria of 4.7 (2.0–11.2), 4.6 (1.8–11.5), and 6.1
(2.3–16.0) respectively. The sensitivity and specificity for the
biomarkers at their respective cut-points are shown in Table 2.
Predicting Placental Malaria using Combinations of
Biomarkers
We hypothesized that combinations of biomarkers would
improve diagnostic accuracy, as each protein could contribute
unique information to a predictive model. Therefore, we generated
a biomarker score based on dichotomization and summation of the
individual biomarkers with the best performance: sFlt-1, leptin, and
CRP. For each marker, one point was assigned if the value was
lower (sFlt-1, leptin) or higher (CRP) than the corresponding cut-
point, and zero points were assigned otherwise. None of the
dichotomized biomarkers were significantly correlated (p.0.05 for
all comparisons using Spearman correlation).
ROC curve analysis of the 3 biomarker score yielded an AUC
(95% CI) of 0.83 (0.78-0.86). A score of 1 or more was able to
identify 95.7% of all infections (sensitivity), and a score of 3 had a
specificity of 100% (Figure 2). A score of 2 had a sensitivity and
specificity of 73.9% and 80.9%, respectively. Evaluation of more
parsimonious biomarker scoring systems showed that 2-biomarker
scores incorporating leptin and CRP (AUC=0.78 [0.73–0.82]), as
well as sFlt-1 and CRP (AUC=0.78 [0.74–0.83]), provided similar
discriminative ability to the 3-biomarker score.
Next, we sought to integrate our biomarkers into models that
included established clinical parameters associated with placental
infection, including maternal anemia and febrile symptoms. To do
this, we first generated a clinical score (0–2) based on the presence
of maternal anemia and non-specific febrile symptoms. The
clinical score had an AUC of 0.72 (0.67–0.77) (Figure 2). Then by
combining the 3-marker biomarker score with the clinical score
(into a five-point score), we were able to achieve an AUC of 0.85
(0.81–0.89), which was significantly better at identifying PM
infections than the clinical score alone (p=0.001) (Figure 2), but
not better than the 3-marker biomarker score (p=0.39).
Discussion
It is well-established that malaria in pregnancy increases the risk
of low birth-weight delivery. In some women with placental
malaria, parasites cannot be detected in the peripheral blood.
Such infections are commonly asymptomatic or paucisympto-
matic, yet they are still associated with adverse effects on
pregnancy outcome. The existence of such ‘hidden’ P. falciparum
infections makes it difficult to assess the true impact of malaria in
pregnancy and poses challenges to the implementation of
proposed programs of intermittent screening and treatment [17].
Table 1. Description of Study Population.
Placental smear
positive PM
N=24
Placental and
peripheral smear negative
N=326 P-value
Age (years) 20.5 (18.3–25.3) 20.0 (18.0–23.0) 0.603
Gravidity 1 (1–3.75) 1 (1–2) 0.580
% malaria-positive by histology 100 53.4 ,0.0001
Total # antimalarial doses{ 2.0 (2.0–2.25) 2 (1–3) 0.575
Weight (kg) 56.0 (50.25–60.25) 56.0 (51.0–60.0) 0.754
Height (cm) 155 (150–159) 154 (150–158) 0.743
Temperature (6C) 36.5 (36.0–37.0) 36.1 (36.0–36.6) 0.076
Hemoglobin (g/dL) 10.9 (10.1–12.2) 12.3 (11.1–13.5) 0.003
Any febrile symptoms in last 7 d, n (%) 15 (62.5) 63 (19.3) ,0.0001
Fever in last 7 d, n (%) 9 (37.5) 15 (4.6) ,0.0001
Chills in last 7 d, n (%) 9 (37.5) 22 (6.7) ,0.0001
Headache in last 7 d, n (%) 15 (62.5) 56 (17.2) ,0.0001
Weight of baby (kg) 2.9 (2.5–3.1) 3.0 (2.7–3.3) 0.036
Weeks gestation at delivery 38 (36–40) 39 (38–40) 0.030
Mononuclear cell count* 18.5 (13.25–30.75) 3 (0–13) ,0.0001
Mononuclear cell pigment score (0–4)* 1.0 (0.25–2.0) 0 (0–0) ,0.0001
Fibrin pigment score (0–4)* 2.0 (0–3.0) 0 (0–1) ,0.0001
Data are presented as median (interquartile range) unless otherwise indicated.
Groups were compared using the Mann-Whitney U test (for continuous variables) or Pearson Chi-square (for nominal variables).
{Number of doses of SP recorded on antenatal clinic card.
*Assessed using a semi-quantitative scale by a single observer.
doi:10.1371/journal.pone.0028540.t001
Biomarkers of Occult Placental Malaria
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28540In this study we assessed the utility of host biomarkers to identify
occult PM infections in a case-control study of Malawian women.
We compared peripheral plasma levels of these biomarkers
between women with placental smear-positive P. falciparum
infections (peripheral blood smear negative) and placental smear-
negative controls. We identified three biomarkers that were
significantly associated with the presence of placental parasites
(sFlt-1, leptin, CRP) and evaluated the diagnostic performance of
these biomarkers alone and in combination using a simple scoring
system. The biomarker score was associated with occult PM
infections, had good diagnostic performance, and allowed more
accurate prediction of placental malaria than a score based on
clinical criteria alone. Our data suggest that a combinatorial
biomarker score could be used to identify women likely to benefit
from targeted anti-malarials during pregnancy.
sFlt-1 is an anti-angiogenic protein that is an alternatively spliced
variant of Flt-1 (VEGFR-1). Elevated sFlt-1 has been implicated in
the pathophysiology of placental malaria [13,15,18] and has also
been identified as a biomarker that is elevated in pregnancy-
associated hypertension and preeclampsia [15,19,20,21]. We
Figure 1. Biomarkers of Occult Placental Malaria Infection. (A-C) Box plots showing the median (IQR) of peripheral blood biomarkers
(whiskers denote the 5-95% percentiles and outliers are plotted as dots), with the associated (D-F) receiver operating characteristic (ROC) curves and
(G-I) decision plots of sensitivity and specificity generated from the ROC curves. Diagnostic accuracy was assessed using receiver operating
characteristic (ROC) curves and determining the area under the ROC curve (AUC). The AUC were compared and all three biomarkers had comparable
diagnostic performance (method of Delong et al.). The dotted lines represent the cut-point for dichotomizing the biomarkers, as defined using the
Youden index.
doi:10.1371/journal.pone.0028540.g001
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infections that were peripheral smear negative compared to
controls. The identification of decreased sFlt-1 in maternal
peripheral blood in malaria is a novel finding, and these data
suggest that sFlt-1 may be particularly useful as a blood test in
pregnancy in malaria-endemic areas, with decreases in sFlt-1 being
Table 2. Peripheral Plasma Biomarkers in Occult Placental Malaria Infections.
Infected Uninfected P-value AUC
a Cut-point Sensitivity Specificity
CRP
b 60.2 (16.7–72.7) 18.5 (8.2–39.7) 0.002* 0.71 (0.66–0.76) 30.5 73.9 (51.6–89.8) 68.3 (62.9–73.4)
C3a
b 2.0 (1.6–4.4) 2.4 (1.6–4.5) 0.704 0.56 (0.50–0.60) 6.4 50.0 (29.1–70.9) 66.0 (60.5–71.1)
C5a 63.0 (32.2–76.1) 58.1 (39.9–78.4) 0.307 0.53 (0.47–0.58) 35.4 34.8 (16.4–57.3) 81.5 (76.8–85.6)
Ang-1 13.7 (6.7–20.6) 17.9 (9.4–32.2) 0.037 0.62 (0.57–0.67) 8.5 43.5 (23.2–65.5) 79.9 (75.1–84.2)
Ang-2 4.4 (2.8–7.7) 5.1 (3.2–7.9) 0.555 0.54 (0.49–0.59) 2.9 34.8 (16.4–57.3) 84.3 (79.9–88.1)
sTie-2 28.9 (22.1–32.1) 24.6 (20.0–30.4) 0.311 0.60 (0.55–0.65) 27.8 60.9 (38.5–80.3) 64.6 (59.1–69.8)
sEndoglin 43.0 (29.0–72.6) 46.7 (36.5–57.5) 0.819 0.49 (0.43–0.54) 69.95 30.4 (13.2–52.9) 90.6 (86.8–93.6)
sFlt-1 16.9 (11.4–34.7) 27.3 (19.3–39.7) 0.003* 0.70 (0.64–0.74) 16.9 52.2 (30.6–73.2) 83.7 (79l2–87.6)
VEGF 0.10 (0.04–0.23) 0.14 (0.06–0.41) 0.242 0.57 (0.52–0.63) 0.075 47.8 (26.8–69.4) 70.2 (64.9–75.2)
Tissue Factor 0.10 (0.06–0.14) 0.08 (0.05–0.14) 0.370 0.56 (0.50–0.61) 0.043 95.5 (77.2–99.9) 23.8 (19.1–29.4)
Leptin 5.6 (4.7–9.8) 11.2 (7.4–18.9) ,0.001* 0.73 (0.67–0.77) 8.8 73.9 (51.6–89.8) 66.5 (61.0–71.6)
Groups (infected vs. uninfected) were compared using the Mann-Whitney U test.
*Significant (p,0.05) after Holm’s correction for 11 pair-wise comparisons. AUC- area under the receiver operating characteristic curve (95% CI),
aNon-parametric estimation (DeLong et al., 1988 estimated using binomial exact method (MedCalc)). Biomarkers are ng/mL unless otherwise indicated-
bmg/mL.
doi:10.1371/journal.pone.0028540.t002
Figure 2. Combinations of Biomarkers and Clinical Parameters Improve Diagnostic Accuracy. (A–C) We generated a simple scoring
system based on the summation of dichotomous variables that were significantly associated with the presence of smear positive parasites in the
placenta, but not the periphery. (A) The clinical score (0–2) consisted of maternal anemia (1) and non-specific febrile symptoms (any one of: fever,
chills, headache=1). (B) The biomarker score (0–3) consisted of high CRP levels (.30.5 mg/mL=1), low leptin levels (,8.8 ng/mL=1), and low sFlt-1
levels (,16.9 ng/mL=1). (C) The clinical score and biomarker score were integrated to generate the final score (0–5). (D) The diagnostic ability of the
different scoring systems was assessed using ROC curve analysis. The clinical + biomarker score had an AUC of 0.85 (95% CI, 0.81-0.89) and was
significantly better than the clinical score at discriminating between women with occult PM infections compared to smear-negative controls,
p=0.001 (method of Delong, et al.).
doi:10.1371/journal.pone.0028540.g002
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predicting the onset of preeclampsia. Further studies will be
required to assess the utility of this marker in populations where
PM and preeclampsia may interact to drive adverse pregnancy
outcomes [15].
Leptin is a peptide hormone that influences energy homeostasis
and regulates neuroendocrine function, in addition to its role as an
inflammatory molecule in immune function. The syncytiotropho-
blast produces an abundance of leptin in later stages of pregnancy
and decreased leptin levels in pregnancy have been associated with
fetal growth restriction [22,23]. We observed a significant
reduction in maternal leptin levels in occult PM compared to
controls. As most placentally-derived leptin is released into the
maternal circulation [24], we postulate that PM infection may
reduce the release of leptin into the maternal circulation.
CRP is an acute phase reactant and a non-specific marker of
inflammation. Our results indicate that CRP is elevated in occult
PM infections, which is consistent with a previous report from
Gabon that described elevated CRP in PM, but not sub-
microscopic infections (assessed by PCR) [25]. In this study,
CRP was the best single predictor with the highest AUC. It is an
attractive candidate biomarker given its commercial availability
and widespread use in other conditions. However, owing to its lack
of specificity, the utility of CRP as a biomarker of occult PM
requires further investigation in studies that include other common
infections in pregnancy such as chorioamnionitis [26].
Combinations of biomarkers have sometimes been shown to
provide better diagnostic or prognostic accuracy than single
markers, particularly if drawn from distinct pathobiological
pathways [27]. In this study, we combined markers of angiogenesis
(sFlt-1), metabolism (leptin), and inflammation (CRP) to improve
identification of occult PM infections. By combining the three
biomarkers with the highest individual AUC, we were able to
achieve better predictive ability than with any of the biomarkers
used on their own (comparison of AUC between 3 biomarker
model and individual models by method of Delong et al., p,0.05).
Assays for both CRP and sFlt-1 have been commercialized and are
available for immediate use. We were able to integrate the
biomarker data with easily obtained clinical data (self-reported
febrile symptoms, anemia) to generate a simple scoring system
with an AUC of 0.85.
While the results of this study are promising, they require
validation in other populations with differing levels of malaria
endemicity. In this population, submicroscopic PM infections were
not associated with differences in biomarkers or with maternal
(anemia, signs and symptoms of disease) or fetal outcome (birth
weight); however, this may not be the case in all populations. The
biomarkers that we have examined will need to be assessed
prospectively together with other inflammatory biomarkers that
have recently been associated with placental malaria [28], and
alongside malaria rapid diagnostic tests and PCR to compare
performance and to determine whether they could be combined to
improve PM diagnosis. The biomarkers discussed in this study will
need to be evaluated at earlier stages in pregnancy, at times when
presumptive therapy might usefully be applied, as well as in the
context of other clinically important infections, in particular HIV.
The case-control design of this study enabled us to look at
biomarkers in a broader context by removing the effect of age and
gravidity on susceptibility to PM. Future studies should validate
these biomarkers in a prospective study.
Conclusion
Biomarkers circulating in the peripheral blood of pregnant
women may provide more accurate prediction of placental malaria
than clinical indicators alone, in women without peripheral
parasitaemia. Analysis of biomarkers in peripheral blood could
contribute to the accurate identification of women most in need of
antimalarial therapy in pregnancy, and thereby facilitate programs
of intermittent screening and therapy aimed at reducing the
impact of malaria on the pregnant woman and unborn child.
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